s6y

OncoMed Pharmaceuticals Inc

CIK
1302573
Industry
Pharmaceutical Preparations

Financials 23

  1. 10-K Annual Report for period ending Dec 31, 2018
  2. 10-Q Quarterly Report for period ending Sep 30, 2018
  3. 10-Q Quarterly Report for period ending Jun 30, 2018
  4. 10-Q Quarterly Report for period ending Mar 31, 2018
  5. 10-K Annual Report for period ending Dec 31, 2017
  6. 10-Q Quarterly Report for period ending Sep 30, 2017
  7. 10-Q Quarterly Report for period ending Jun 30, 2017
  8. 10-Q Quarterly Report for period ending Mar 31, 2017
  9. 10-K Annual Report for period ending Dec 31, 2016
  10. 10-Q Quarterly Report for period ending Sep 30, 2016

All 23 financials filings

News 55

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 55 news filings

Ownership 351

  1. SC 13D/A Major Shareholders
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. SC 13D Major Shareholders

All 351 ownership filings

Prospectus 43

  1. S-8 POS Post-effective amendment to a S-8 registration statement
  2. S-8 POS Post-effective amendment to a S-8 registration statement
  3. S-8 POS Post-effective amendment to a S-8 registration statement
  4. S-8 POS Post-effective amendment to a S-8 registration statement
  5. S-8 POS Post-effective amendment to a S-8 registration statement
  6. S-8 POS Post-effective amendment to a S-8 registration statement
  7. 425 Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
  8. 425 Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
  9. 425 Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
  10. 425 Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

All 43 prospectus filings

Proxies 12

  1. DEFM14A Definitive proxy statement relating to a merger, acquisition, or disposition
  2. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  3. DEF 14A Definitive proxy statements
  4. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  5. DEF 14A Definitive proxy statements
  6. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  7. DEF 14A Definitive proxy statements
  8. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  9. DEF 14A Definitive proxy statements
  10. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.

All 12 proxies filings

Other 42

  1. 15-12B Notice of termination of registration of a class of securities under Section 12(b)
  2. 25-NSE Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
  3. CT ORDER Order Granting Confidential Treatment
  4. EFFECT Notice of Effectiveness
  5. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  6. CT ORDER Order Granting Confidential Treatment
  7. UPLOAD Letter (PDF)
  8. CT ORDER Order Granting Confidential Treatment
  9. CT ORDER Order Granting Confidential Treatment
  10. CT ORDER Order Granting Confidential Treatment

All 42 other filings